Lucid Diagnostics Inc.

Lucid reported Q1 revenue of $1.3 million on 3,177 EsoGuard tests, with billable value of over $8.7 million at a list price of $27.49. Cash at quarter end was $27.9 million, rising to $44.8 million pro forma including the April 24 financing that brought in approximately $16.8 million. Non-GAAP net loss per share was $0.07, better by about $0.03 versus each of the prior three quarters, and non-GAAP operating expenses were $11.7 million, roughly in line with the previous five-quarter average. Management did not give formal next-quarter or full-year revenue guidance, but said the balance sheet support extends runway well into 2027 and that the burn rate should stay around recent levels while investments continue to support commercial expansion.

Dr. Aklog framed the quarter around commercial and reimbursement progress rather than near-term reported revenue, emphasizing that the company is building infrastructure for a Medicare launch. He repeatedly said the Medicare delay is a logistics issue, not a concern about the substance of the case, and pointed to the CAC meeting and follow-up discussions as support for a positive outcome. He was also notably upbeat about VA traction, commercial payer discussions, and strong interest coming out of DDW, where guidelines previewed EsoGuard and EsoCheck by name.

Dennis McGrath highlighted a stronger balance sheet, with $27.9 million in cash at quarter end and $44.8 million pro forma after financing. He said average burn over the last four quarters was $11.3 million per quarter including cash interest, with Q1 a bit higher at $12.1 million because of investments in sales, clinical services, and market access. He also noted the convertible notes carried a fair value of $25.2 million at quarter end, a $1.2 million quarterly mark-to-market increase, and that Q1 non-GAAP operating expenses were $11.7 million, in line with the recent average.

Analysts focused on Medicare timing, MolDX/LCD delays, and whether commercial payers are waiting for CMS. Management said there is no concrete timing update, but the delay looks logistical and they remain confident the draft LCD will ultimately be positive. On VA, management said the first quarter was mainly about building the pipeline and that no VA revenue contributed yet, while confirming the VA contract is separate from Medicare and reimburses directly at the Medicare-rate contract level. Management also said the first quarter government mix was 13% of claims, that the first LBM coverage policy has been secured but not yet published, and that the sales team remains focused on revenue-generating segments including Medicare, VA, and contracted business.